Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria: * Histologically confirmed solid tumor or lymphomas (Accrual for Lymphoma Patients Closed as of 11/27/09) * Refractory to standard treatment OR no standard treatment that is potentially curative or capable of prolonging life expectancy exists * Tumor amenable to biopsy (patients accrued at the MTD only) * No CNS metastases * Performance status - ECOG 0-2 * At least 12 weeks * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Bilirubin ≤ 2 times upper limit of normal (ULN) * AST ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2 times ULN (5 times ULN if due to liver involvement) * Creatinine ≤ 2 times ULN * QTc \< 500 msec for men (470 msec for women) * LVEF \> 40% by echocardiogram * Ejection fraction normal by echocardiogram (for patients who have received prior anthracycline therapy) * No cardiac symptoms ≥ grade 2 * No New York Heart Association class III or IV heart failure * No myocardial infarction within the past year * No active ischemic heart disease within the past year * No congenital long QT syndrome * No left bundle branch block * No history of uncontrolled dysrhythmias or requiring antiarrhythmic drugs * No history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine) * No poorly controlled angina * No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) * No other significant cardiac disease * Pulse oximetry at rest and exercise \< 88% (per Medicare guidelines) * No pulmonary symptoms ≥ grade 2 * No significant pulmonary disease requiring oxygen supplementation or causing a severe limitation in activity * No symptomatic pulmonary disease requiring medication including any of the following: * Dyspnea on or off exertion * Paroxysmal nocturnal dyspnea * Oxygen requirement and significant pulmonary disease, including chronic obstructive/restrictive pulmonary disease * No home oxygen use that meets the Medicare criteria * No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine) * No seizure disorder * No sensory peripheral neuropathy \> grade 1 * No neuropathic pain of any etiology * Patients with residual peripheral neuropathy ≤ grade 1 due to oxaliplatin therapy allowed * No uncontrolled infection * No prior serious allergic reaction to eggs * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, or Mayo Clinic Florida for follow up * More than 4 weeks since prior immunotherapy or biologic therapy * No concurrent prophylactic colony-stimulating factors * No concurrent immunotherapy, biologic therapy, or gene therapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * No other concurrent chemotherapy * Concurrent steroids (at a stable dose for ≥ 4 weeks) for comorbid conditions (e.g., adrenal insufficiency or rheumatoid arthritis) allowed * More than 4 weeks since prior radiotherapy * No prior radiotherapy that potentially included the heart in the field (e.g., mantle) or chest * No prior radiotherapy to \> 25% of bone marrow * No prior radiopharmaceuticals * No concurrent radiotherapy * Recovered from prior therapy * More than 8 weeks since prior UCN-01 * No concurrent warfarin * Low molecular weight heparin allowed * No concurrent medications that prolong or may prolong QTc interval * No other concurrent investigational therapy